Event-free (a, c) and overall (b, d) survival of limited stage PTCL (PTCL-NOS, AITL, ALCL) patients who received front-line combination chemotherapy with (—) or without (·····) radiotherapy. A landmark analysis, including those who achieved a complete or partial remission following front-line combination chemotherapy, is shown (c, d).